Iovance Biotherapeutics Shares Soar 14.46% on FDA Approval, Leadership Changes

Iovance Biotherapeutics Inc. shares surged 14.46% in pre-market trading on July 22, 2025, driven by positive developments in its cancer treatment pipeline and strategic leadership changes.

Iovance's stock price has been on an upward trajectory following the FDA's approval of its cancer treatment, Amtagvi, and the release of promising clinical trial results. These developments have bolstered investor confidence in the company's ability to deliver innovative cancer therapies.

Despite reducing its guidance, Iovance remains optimistic about its financial performance, projecting $275 million in product revenue for 2025, primarily from Amtagvi. This outlook has contributed to the positive market sentiment surrounding the company.

Iovance has also made significant strides in its leadership, appointing Corleen Roche as its new CEO. Roche brings a wealth of experience in biotech financial management and commercial launches, which is expected to further enhance the company's strategic direction and operational efficiency.